Canada
· Delayed Price · Currency is CAD Appili Therapeutics Statistics
Total Valuation
Appili Therapeutics has a market cap or net worth of CAD 4.24 million. The enterprise value is 12.33 million.
| Market Cap | 4.24M |
| Enterprise Value | 12.33M |
Important Dates
The next estimated earnings date is Friday, August 9, 2024.
| Earnings Date | Aug 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Appili Therapeutics has 121.27 million shares outstanding. The number of shares has increased by 6.62% in one year.
| Shares Outstanding | 121.27M |
| Shares Change (YoY) | +6.62% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | n/a |
| Float | 106.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.13 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.26 |
| EV / Sales | 14.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.95 |
Financial Position
The company has a current ratio of 0.13
| Current Ratio | 0.13 |
| Quick Ratio | 0.11 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.28 |
| Interest Coverage | -4.94 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -217.68% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 9 |
| Asset Turnover | 0.36 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Appili Therapeutics has paid 69,584 in taxes.
| Income Tax | 69,584 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.36% in the last 52 weeks. The beta is 1.10, so Appili Therapeutics's price volatility has been similar to the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | -36.36% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.04 |
| Relative Strength Index (RSI) | 44.30 |
| Average Volume (20 Days) | 212,140 |
Short Selling Information
The latest short interest is 12,229, so 0.01% of the outstanding shares have been sold short.
| Short Interest | 12,229 |
| Short Previous Month | 47,047 |
| Short % of Shares Out | 0.01% |
| Short % of Float | 0.01% |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Appili Therapeutics had revenue of CAD 827,407 and -3.78 million in losses. Loss per share was -0.03.
| Revenue | 827,407 |
| Gross Profit | 827,407 |
| Operating Income | -8.05M |
| Pretax Income | -3.71M |
| Net Income | -3.78M |
| EBITDA | -8.04M |
| EBIT | -8.05M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 94,493 in cash and 8.18 million in debt, giving a net cash position of -8.09 million or -0.07 per share.
| Cash & Cash Equivalents | 94,493 |
| Total Debt | 8.18M |
| Net Cash | -8.09M |
| Net Cash Per Share | -0.07 |
| Equity (Book Value) | -10.92M |
| Book Value Per Share | -0.09 |
| Working Capital | -10.08M |
Cash Flow
In the last 12 months, operating cash flow was -2.46 million and capital expenditures -29,717, giving a free cash flow of -2.49 million.
| Operating Cash Flow | -2.46M |
| Capital Expenditures | -29,717 |
| Free Cash Flow | -2.49M |
| FCF Per Share | -0.02 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -972.94% |
| Pretax Margin | -448.55% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -301.44% |
Dividends & Yields
Appili Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.62% |
| Shareholder Yield | -6.62% |
| Earnings Yield | -89.08% |
| FCF Yield | -58.76% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |